LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

IQVIA Holdings Inc

Fechado

SetorSaúde

178.97 5.04

Visão Geral

Variação de preço das ações

24h

Atual

Mín

176.83

Máximo

179.25

Indicadores-chave

By Trading Economics

Rendimento

182M

514M

Vendas

264M

4.4B

P/E

Médio do Setor

20.703

108.767

Margem de lucro

11.778

Funcionários

93,000

EBITDA

1B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+27.12% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-12B

28B

Abertura anterior

173.93

Fecho anterior

178.97

Sentimento de Notícias

By Acuity

6%

94%

3 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

IQVIA Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de fev. de 2026, 23:53 UTC

Ações em Alta

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 de fev. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28 de fev. de 2026, 21:36 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 de fev. de 2026, 15:20 UTC

Ganhos

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 de fev. de 2026, 14:43 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 de fev. de 2026, 14:38 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 de fev. de 2026, 13:47 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 de fev. de 2026, 13:44 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 de fev. de 2026, 13:14 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 de fev. de 2026, 02:32 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 de fev. de 2026, 02:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 de fev. de 2026, 02:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Six Months, 9 Offers and $81 Billion. How -2-

28 de fev. de 2026, 00:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 de fev. de 2026, 23:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 de fev. de 2026, 23:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 de fev. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

27 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

27 de fev. de 2026, 21:30 UTC

Ganhos

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 de fev. de 2026, 21:30 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 de fev. de 2026, 21:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 de fev. de 2026, 21:17 UTC

Ganhos

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 de fev. de 2026, 21:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 de fev. de 2026, 21:09 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 de fev. de 2026, 21:00 UTC

Ganhos

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 de fev. de 2026, 20:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 de fev. de 2026, 20:24 UTC

Conversa de Mercado

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 de fev. de 2026, 20:23 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 de fev. de 2026, 20:12 UTC

Conversa de Mercado

Nike Seen With Further Challenges in China -- Market Talk

27 de fev. de 2026, 19:44 UTC

Conversa de Mercado

Gold Caps Historic Month -- Market Talk

27 de fev. de 2026, 19:39 UTC

Ganhos

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Comparação entre Pares

Variação de preço

IQVIA Holdings Inc Previsão

Preço-alvo

By TipRanks

27.12% parte superior

Previsão para 12 meses

Média 227.31 USD  27.12%

Máximo 256 USD

Mínimo 174 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para IQVIA Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

16 ratings

12

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

150.68 / 153.45Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

3 / 352 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat